▁type ▁ 2 ▁di ab etes , ▁and ▁dar ap lad ib ▁for ▁a ther os cl eros is , ▁and ▁in ▁September , ▁sold ▁its ▁be verage ▁division ▁to ▁S unt ory . ▁This ▁included ▁the ▁br ands ▁Lu co za de ▁and ▁Rib ena ; ▁however , ▁the ▁deal ▁did ▁not ▁include ▁Hor lick s . ▁ ▁In ▁March ▁ 2 0 1 4 , ▁G SK ▁paid ▁US $ 1 b ill ion ▁to ▁raise ▁its ▁st ake ▁in ▁its ▁Indian ▁ph arma ce ut ical ▁unit , ▁Gla x o Smith K line ▁Ph arma ce ut ical s , ▁to ▁ 7 5 ▁percent ▁as ▁part ▁of ▁a ▁move ▁to ▁focus ▁on ▁emer ging ▁mark ets . ▁In ▁April ▁ 2 0 1 4 , ▁Nov art is ▁and ▁Gla x o ▁agreed ▁on ▁more ▁than ▁US $ 2 0 b ill ion ▁in ▁de als , ▁with ▁Nov art is ▁s elling ▁its ▁v acc ine ▁business ▁to ▁G SK ▁and ▁bu ying ▁G SK ' s ▁cancer ▁business . ▁In ▁February ▁ 2 0 1 5 , ▁G SK ▁announced ▁that ▁it ▁would ▁ac quire ▁G ly co V ax yn , ▁a ▁Swiss ▁ph arma ce ut ical ▁company , ▁for ▁US $ 1 9 0 mill ion , ▁and ▁in ▁June ▁that ▁year ▁that ▁it ▁would ▁sell ▁two ▁men ing itis ▁dru gs ▁to ▁Pf izer , ▁N imen rix ▁and ▁M ence v ax ▁for ▁around ▁US $ 1 3 0 mill ion